NORTHERN-DATA-AG
8.4.2021 15:18:11 CEST | Business Wire | Press release
Northern Data AG (XETRA: NB2 , ISIN: DE000A0SMU87 ), a leading developer and operator of High-Performance-Computing ("HPC") infrastructure solutions, sells its U.S. subsidiary Whinstone Inc., which operates a high-performance data center facility based in Rockdale, Texas, to Riot Blockchain Inc. (NASDAQ: "RIOT"), one of the largest U.S. based publicly-traded bitcoin miners in North America. The consideration in the transaction consists of EUR 67 million in cash component (cash and debt-free) and 11.8 million shares of common stock of Riot Blockchain Inc., which, based on the Riot Blockchain Inc. last closing share price (record date April 7, 2021: USD 48.37), corresponds to a total value of EUR 481 million. Consequently, the total volume of the transaction amounts to approximately EUR 548 million. Upon closing of the transaction, Northern Data AG will own approximately 12% of the total outstanding common stock of Riot Blockchain Inc.
Northern Data AG pursues a multi-site strategy with strong focus on value-accretive HPC business. The Company's leadership in cost, speed, availability and scale maximizes hardware profitability and is rewarded by adequate profit share agreements as well as fix base remunerations.
The Company pursues a clear strategic roadmap using the transaction proceeds to further expand its six existing HPC locations in Canada, Germany, the Netherlands and Scandinavia, including the new ultra-efficient Boden Facility in Sweden. Given all sites in operation and construction are already sold out, the proceeds will allow Northern Data to directly accelerate the development of eight new HPC locations in North America and Europe. Concerning the eight new sites in development, the Company further diversifies geographically and will expand even beyond in the coming years.
The sites stand out by time to market of 2-4 months, data sovereignty principles, tier 3 DC standards and sustainability attributes such as renewable energy usage of >90%, mild climate (around 6 degrees C) and Northern Data's proprietary software-controlled cooling solution leading to an above-market standard power usage effectiveness (PUE) of around 1.04. All newly developed sites are entirely green and the Company is building towards a circular ecosystem.
The Company's strategic roadmap is set and the corresponding growth goals for the next years are already covered by the new sites in planning as well as the placed hardware orders. As a result, the Company will be able to meet the exponentially growing customer demand for high-performance computing power for a broad range of applications, including artificial intelligence, autonomous driving, graphics rendering, blockchain businesses such as Bitcoin mining and other scientific use cases.
Riot intends to not only utilize Whinstone's existing operational capacity for their own mining operations but also to scale capacity and establish themselves as the leading Bitcoin miner in the US. By becoming a minority shareholder in Riot going forward, through its equity stake in Riot, Northern Data will be able to benefit from the synergies generated by the transaction and continues to directly participate in the growth of Bitcoin value potential.
"Northern Data has been able to create a versatile multi-site network of efficient HPC capabilities with an industry-leading sustainability focus by offering secured access to renewable energy sources. With the proceeds from the transaction, we can accelerate our expansion significantly and reinforce the focus on value-accretive HPC services," said Aroosh Thillainathan, CEO of Northern Data AG.
Due to the strong, profitable growth of the other data center sites the operating EBITDA forecast for 2021 in the order of EUR 100 million to EUR 125 million remains unchanged. The operating EBITDA forecast includes the YTD business performance, but no one-off effects from the transaction and effects from the current fiscal year of Whinstone US Inc. in the order of a mid-three-digit million-euro range. Accordingly, the reporting of Northern Data AG will be continued without the consolidation of Whinstone US Inc. in the future. The company now expects to generate revenues in the amount of EUR 285 million to EUR 325 million in fiscal year 2021. Originally, revenues of EUR 350 million to EUR 400 million and EBITDA of EUR 100 million to EUR 125 million were forecast. For the years to come, management expects a continuation of the strong profitable growth.
Greenhill is serving as exclusive financial adviser to Northern Data. Sullivan & Cromwell LLP is acting as legal counsel to Northern Data.
About Northern Data:
Northern Data AG
develops and operates global infrastructure solutions in the field of High- Performance Computing (HPC). With its customer-specific solutions, the company provides the infrastructure for various HPC applications in areas such as bitcoin mining, artificial intelligence, blockchain, big data analytics, IoT or rendering. The internationally active company was formed from the merger of the German company Northern Bitcoin AG and the American company Whinstone US, Inc. and is today a leading provider of HPC solutions worldwide. Northern Data offers its HPC solutions both in large, stationary data centers and in mobile high-tech data centers that can be set up at any location worldwide. The company combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. The Northern Data group currently employs around 200 people.
| Language: | English |
| Company: | Northern Data AG |
| An der Welle 3 | |
| 60322 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Hanover, Munich (m:access), Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
